225 related articles for article (PubMed ID: 37958416)
1. BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature.
Guerrero P; Albarrán V; San Román M; González-Merino C; García de Quevedo C; Moreno J; Calvo JC; González G; Orejana I; Chamorro J; Martínez-Delfrade Í; Morón B; de Frutos B; Ferreiro MR
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958416
[TBL] [Abstract][Full Text] [Related]
2. Management of
Takeda H; Sunakawa Y
Front Oncol; 2021; 11():602194. PubMed ID: 33842313
[No Abstract] [Full Text] [Related]
3. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Analysis of Treatment Pathways in Patients With BRAF
Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
[TBL] [Abstract][Full Text] [Related]
5. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer.
Grassi E; Corbelli J; Papiani G; Barbera MA; Gazzaneo F; Tamberi S
Front Oncol; 2021; 11():601722. PubMed ID: 34249672
[TBL] [Abstract][Full Text] [Related]
6. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients.
Aasebø KØ; Dragomir A; Sundström M; Mezheyeuski A; Edqvist PH; Eide GE; Ponten F; Pfeiffer P; Glimelius B; Sorbye H
Cancer Med; 2019 Jul; 8(7):3623-3635. PubMed ID: 31070306
[TBL] [Abstract][Full Text] [Related]
7. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
8. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
[TBL] [Abstract][Full Text] [Related]
9. Advances in the therapy of BRAF
Jin Z; Sinicrope FA
Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
[No Abstract] [Full Text] [Related]
10. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
[TBL] [Abstract][Full Text] [Related]
11. Emerging treatment options for
Ursem C; Atreya CE; Van Loon K
Gastrointest Cancer; 2018; 8():13-23. PubMed ID: 29628780
[TBL] [Abstract][Full Text] [Related]
12. Encorafenib plus cetuximab for the treatment of
Ros J; Saoudi N; Baraibar I; Salva F; Tabernero J; Elez E
Therap Adv Gastroenterol; 2022; 15():17562848221110644. PubMed ID: 35812780
[TBL] [Abstract][Full Text] [Related]
13. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
Wang Q; Shen X; Chen G; Du J
Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation.
Digiacomo N; Bolzacchini E; Veronesi G; Cerutti R; Sahnane N; Pinotti G; Bregni M; Artale S; Verusio C; Crivelli F; Capella C; Sessa F; Furlan D
Clin Colorectal Cancer; 2019 Jun; 18(2):e251-e260. PubMed ID: 30638691
[TBL] [Abstract][Full Text] [Related]
15. Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability.
Borelli B; Antoniotti C; Carullo M; Germani MM; Conca V; Masi G
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291761
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review.
DeStefanis RA; Kratz JD; Emmerich PB; Deming DA
Curr Colorectal Cancer Rep; 2019 Apr; 15(2):61-69. PubMed ID: 31130830
[TBL] [Abstract][Full Text] [Related]
17. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
[TBL] [Abstract][Full Text] [Related]
18. General treatment for metastatic colorectal cancer: From KEYNOTE 177 study.
Ding Y; Weng S; Li X; Zhang D; Aisa A; Yuan Y
Transl Oncol; 2021 Aug; 14(8):101122. PubMed ID: 34030111
[TBL] [Abstract][Full Text] [Related]
19. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
